Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases
The conference will focus on translational studies geared towards therapies in AD and related neurodegenerative disease with discussion of the latest advances and the future challenges in the field
Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide. Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD since 2003. Other related neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are also age-dependent and lack effective therapies. Hence, finding cures for AD and other related neurodegenerative diseases is urgent and various approaches should be actively pursued. This planed conference intends to bring leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees and to share their vision or prospects on translational research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets or approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries, including presentations of clinical trial results. The talks and poster presentations will include the most updated therapeutic strategies, newly discovered therapeutic targets, and recent clinical developments at various stages in the area of Alzheimer’s and related neurodegenerative diseases.
For sponsorship opportunities contact Fusion Conferences.
Please note registration fees include fixed accommodation (1, 2 and 3 June 2018), an all-inclusive food & beverage package and conference attendance.
On Friday June 1, 2018 at 2:00 pm (ends Monday June 4, 2018 at 12:00 pm)